Our comprehensive diagnostic service covers all modalities including pathology, radiology and genetics, led by nationally recognised consultants and supported by dedicated on-site clinical teams.
Within our network of state-of-the-art centres, we offer a comprehensive pathology service covering many different specialities, including breast, prostate and gynaecology. We use the latest proven screening and diagnostic techniques, conducted by experienced clinicians.
The pathology tests available at GenesisCare are listed below and you can read more on our patient site.
Our expert nuclear medicine physicians, radiographers and radiologists use the latest-generation technology to perform and interpret the scans. As well as established methods of scanning, we also use innovative solutions to identify disease and plan your treatments, such as PSMA PET/CT for prostate cancer and fMRI to examine the brain.
The radiology services available at GenesisCare are listed below and you can read more on our patient site.
We’re pioneering the use of genomic profiling in the diagnostic pathway for all solid tumours, leukaemias, lymphomas or sarcomas.
We also offer BRCA-1 and BRCA-2 genetic testing for breast and ovarian screening.
Multi-modal MR imaging guides cognitive and neurological outcomes for patients with primary brain tumours and brain metastases.
Functional MRI (fMRI) is a non-invasive imaging technique that is able to indirectly measure brain activity using fluctuations in brain energy demands related to neural signalling.1
We use fMRI to locate eloquent brain tissue related to speech, vision, movement, etc., as well as guide neurosurgical planning and tailor surgery for intrinsic brain tumours to avoid neurological deficit and improve patient outcomes. With the increasing neuro-oncological benefits of surgery for brain tumours, fMRI offers potential further applications to measure brain recovery processes to optimally stage and monitor treatments.2
Generally, fMRI shows high agreement with clinical gold standard tests, such as the amytal test and intraoperative direct brain stimulation, but importantly offers the advantage of being safe and non-invasive.
In addition, patients are offered a complementary MRI technique called diffusion tensor imaging (DTI). This imaging scan provides assessment of tissue microstructure and we use tractography to provide a 3D visualisation of neural tracts and the brain’s connectivity. This provides additional information about the location of important pathways for speech, movement, vision and other behaviours important for patient quality of life, whereas conventional MRI techniques provide only anatomical information.
These innovations that preserve quality of life are crucial to our approach to neuro-oncology which is to treat the whole patient, and not just the tumour. We are the first private service to offer this to our patients in the UK.
DTI determines proximity of language tracts
fMRI determines proximity of language activity